GlassScriptPhysician profile
Rejan C Mccaskill
NPI 1790852606
$2,972.24
in general payments reported to CMS, 2019-2025
32 companies · $32.54 in 2025
The $32.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $912 · 2021: $314 · 2022: $169 · 2023: $186 · 2025: $32.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $329.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $275.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $244.35 | 2019-2020 | |
| Novo Nordisk INC | $241.81 | 2019-2025 | Ozempic |
| Abbvie INC. | $230.33 | 2019-2023 | |
| Amgen INC. | $182.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $153.03 | 2019-2020 | |
| Ibsa Pharma INC. | $139.87 | 2019-2022 | |
| Genzyme Corporation | $121.99 | 2023 | |
| Allergan, INC. | $112.29 | 2019-2020 | |
| Astellas Pharma US INC | $108.64 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.36 | 2019-2020 | |
| Eisai INC. | $81.08 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $75.13 | 2019-2020 | |
| Lilly USA, LLC | $74.96 | 2019-2025 | Mounjaro |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $70.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.12 | 2020-2022 | |
| Daiichi Sankyo INC. | $66.75 | 2019-2021 | |
| Radius Health, INC. | $39.47 | 2021 | |
| Sanofi Pasteur INC. | $36.43 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.18 | 2019 | |
| Seqirus USA INC | $27.80 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.59 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.40 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.38 | 2020 | |
| Exact Sciences Corporation | $18.39 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.75 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $17.70 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.64 | 2019 | |
| Currax Pharmaceuticals LLC | $14.15 | 2020 | |
| Endo Pharmaceuticals INC. | $12.48 | 2020 | |
| Sanofi-Aventis U.S. LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rejan Mccaskill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.